Our Network of Board-Certified Providers
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Residents of the University District area of Missoula, Montana now have access to physician-level GLP-1 expertise through our telehealth platform. Our network of MT-licensed physicians includes specialists in obesity medicine, endocrinology, and metabolic health who provide the same depth of expertise for Missoula County patients that was previously only available at top-tier academic medical centers.
GLP-1 medications including semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are prescribed by GLP-1-licensed physicians who understand the nuanced clinical decision-making required to optimize outcomes for Missoula residents. Every treatment plan reflects clinical knowledge in GLP-1 pharmacology, patient selection, and long-term management.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 6, 2026
Ozempic and Wegovy both contain semaglutide, FDA-approved for type 2 diabetes and chronic weight management, respectively. Board-certified physicians prescribe weekly semaglutide injections with personalized dose-escalation protocols informed by each patient's metabolic profile and treatment targets.
Mounjaro (tirzepatide for diabetes) and Zepbound (tirzepatide for obesity) harness the combined power of GLP-1 and GIP receptor agonism. Clinical management requires board-certified physicians skilled in dual-agonist patient selection, dose escalation to maximum 15 mg weekly, and monitoring for gastrointestinal and metabolic responses.
Landmark randomized controlled trials in the New England Journal of Medicine establish the efficacy profile of FDA-approved GLP-1 medications available to University District, Missoula residents:
Telehealth prescribing of GLP-1 receptor agonists in Montana is conducted by board-certified, MT-licensed physicians through HIPAA-compliant platforms. GLP-1 medications are not DEA-scheduled controlled substances and may be prescribed via telehealth after a valid clinical evaluation.
Accessing licensed GLP-1 telehealth care from University District follows a comprehensive, clinical protocol delivered entirely online. No need to travel to academic medical centers from Missoula — our licensed physicians bring the same expertise to your screen.
Complete a thorough, clinical health questionnaire from your home in University District. This comprehensive assessment covers your full medical history, comorbidities, metabolic indicators, current medications, and weight management history — providing your licensed physician with the depth of information needed for clinical prescribing. Takes approximately 2-3 minutes.
A MT-licensed licensed physician conducts a comprehensive telehealth consultation, applying GLP-1 clinical knowledge to your case. They match you with the optimal medication, design a personalized dose-escalation schedule, and establish a physician-level monitoring plan for your entire treatment journey.
Once your licensed approves your prescription, your GLP-1 medication is dispensed from a licensed US pharmacy and delivered directly to your University District address. Most patients in Missoula receive their medication within 3-5 business days, with ongoing physician follow-up to optimize your treatment plan over time.
Our licensed telehealth physicians serve all neighborhoods in Missoula and surrounding areas with the same physician-level GLP-1 protocols.
Expert GLP-1 telehealth services available across every neighborhood in Missoula, MT.
Also offering physician-level GLP-1 expertise in cities near Missoula.
Physician-level GLP-1 telehealth care available in the largest cities across Montana.
Board-certified physicians prescribe FDA-approved GLP-1 medications through our telehealth platform, reaching patients in neighborhoods throughout the United States.
Local weight loss and GLP-1 providers serving the University District, Missoula area, based on Google Business listings.
2412 River Rd %23 C, Missoula, MT 59804
5/5 ★ (15 reviews)
109 S 3rd St W
5/5 ★ (112 reviews)
275 N Russell St suite 3, Missoula, MT 59801
5/5 ★ (226 reviews)
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Physicians serving University District and greater Missoula, Montana specialize in obesity medicine, endocrinology, and metabolic health — not just general practitioners writing prescriptions. They hold MT medical licenses and apply deep GLP-1 pharmacology expertise to every treatment plan, with ongoing physician-level monitoring throughout your therapy.
Licensed physicians serving University District and throughout Missoula go beyond basic prescribing — they optimize dosing schedules, anticipate and manage side effects proactively, adjust treatment plans based on your response, and apply the latest evidence to maximize your weight loss and metabolic outcomes.
Licensed GLP-1 consultations for Missoula patients are conducted through secure, HIPAA-compliant telehealth. Your licensed reviews your complete medical history, metabolic profile, and treatment goals before designing a personalized, physician-guided GLP-1 protocol with a structured follow-up plan.
Our licensed physicians prescribe all FDA-approved GLP-1 medications to eligible Missoula County residents — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda) — selected based on clinical assessment of your individual metabolic profile, comorbidities, and treatment goals.
Our licensed physicians apply the same evidence-based protocols used at leading academic weight management programs. All prescriptions are issued by board-certified, MT-licensed physicians through HIPAA-compliant platforms. Medications come from verified US pharmacies. The expertise is equivalent — the access is far greater.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
